Phase 1 Gemcitabine and Nab-Paclitaxel With or Without Pitavastatin for Unresectable Pancreatic Adenocarcinoma
Summary
A Phase 1, open-label clinical trial (NCT07549958) is evaluating the recommended Phase 2 dose of Gemcitabine with Nab-paclitaxel, with or without Pitavastatin, in subjects with unresectable pancreatic adenocarcinoma (uPDAC). Subjects must already be receiving Gemcitabine for treatment of their disease. The trial studies two conditions: pancreatic cancer and pancreatic cancer metastatic. The study was posted on April 24, 2026.
“This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 1 clinical trial registration for unresectable pancreatic adenocarcinoma has been added to ClinicalTrials.gov. The trial will determine the recommended Phase 2 dose of Gemcitabine with Nab-paclitaxel, with or without the addition of Pitavastatin, in subjects already receiving Gemcitabine treatment. This open-label study enrolls subjects with uPDAC and metastatic pancreatic cancer.
Healthcare providers and clinical investigators involved in pancreatic cancer treatment should be aware that this trial is actively registered and may be recruiting. Pharmaceutical companies developing gemcitabine-based regimens or statin combinations for oncology indications may find this trial relevant for understanding competitive landscape and dosing protocols.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
Phase 1 NCT07549958 Kind: PHASE1 Apr 24, 2026
Abstract
This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.
Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic
Interventions: Pitavastatin
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.